Every Form 4 that CG Oncology, Inc. (CGON) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CGON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGON filings page.
CG Oncology, Inc. (CGON) director Leonard E. Post reported an option exercise and related share sale. On 2026-08-14 he exercised a fully vested director stock option for 1,000 shares of common stock at an exercise price of $0.60 per share, then sold 1,000 shares of common stock at $74.54 per share in a transaction reported as a sale in the open market or a private transaction. After the exercise, he held 104,077 director stock options directly. The sale was carried out under a Rule 10b5-1 trading plan adopted on March 5, 2026.
CG Oncology, Inc. director Leonard E. Post exercised stock options for 1,000 shares of Common Stock at $0.60 per share and on July 15, 2026 sold 1,000 shares at $71.17 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he held no Common Stock directly and 105,077 fully vested Director Stock Options.
CG Oncology, Inc. director James Mulay exercised a fully vested director stock option to acquire 24,165 shares of common stock at an exercise price of $26.63 per share. He then sold 24,165 shares in an open-market transaction at a weighted average price of $75.16 per share.
The sales were executed under a Rule 10b5-1 trading plan adopted on March 27, 2026, with individual sale prices ranging from $74.98 to $75.79. After these transactions, this report shows 0 common shares and 0 related director stock options remaining in the reported accounts.
CG Oncology, Inc. reported an open-market purchase of its Common Stock by Seven Fleet Partners LP, an entity associated with director Brian Guan-Chyun Liu. Seven Fleet Partners LP bought 371,085 shares at $66.87 per share on June 25, 2026, bringing its indirectly reported holdings to 1,886,236 shares.
Liu is the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners LP, and may be deemed to beneficially own these shares. He disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.
CG Oncology director Leonard E. Post reported coordinated stock transactions. On June 24, 2026, he sold 5,000 shares of Common Stock in an open-market transaction at $70.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026.
On the same date, he exercised a director stock option to acquire 5,000 common shares at an exercise price of $0.60 per share. After these moves, he directly owned 5,000 common shares and held 106,077 director stock options expiring on July 8, 2028, indicating an exercise-and-sell pattern with a substantial remaining option position.
CG Oncology director Leonard E. Post reported an option exercise and share sale. On June 22, 2026, he exercised options to acquire 5,000 shares of common stock at $0.60 per share and sold 5,000 shares at $65.00 in an open-market transaction. The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he reported no directly held common shares but retained 111,077 director stock options with a $0.60 exercise price expiring on July 8, 2028.
CG Oncology, Inc. director James Mulay reported an exercise-and-sell transaction in company stock. He exercised options for a total of 1,964 shares of Common Stock at strike prices of $12.59 and $3.72 per share, then sold 1,964 shares in open-market trades at $60.12 per share.
The options exercised were Director Stock Options with expiration dates in 2033. A footnote states the sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026, indicating these dispositions were scheduled in advance rather than timed discretionarily.
CG Oncology director Brian Guan-Chyun Liu received a grant of stock options for 9,354 shares of common stock. These Director Stock Options give him the right to buy shares at an exercise price of $56.09 per share and expire on June 3, 2036.
The options vest over time: 1/12 of the total vests monthly after the June 4, 2026 grant date, as long as he continues serving the company. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested portion will vest on that meeting date.
CG Oncology, Inc. director Victor Edward Tong Jr. received a grant of stock options covering 9,354 shares of common stock. The options have an exercise price of $56.09 per share and expire on June 3, 2036.
These options vest in 12 equal monthly installments after June 4, 2026, the grant date. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested portion vests on the meeting date, contingent on his continued service.
CG Oncology, Inc. director James Mulay received a grant of stock options covering 9,354 shares of common stock. These options have an exercise price of $56.09 per share and expire on June 3, 2036.
Following this grant, Mulay holds options for 9,354 shares directly. According to the vesting terms, 1/12 of the options vest monthly after June 4, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs before the first anniversary, subject to his continuous service.
CG Oncology director Christina Rossi received a stock option grant covering 9,354 shares of common stock. The option has an exercise price of $56.09 per share and expires on June 3, 2036. Vesting occurs in 12 equal monthly installments after June 4, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within the first year, subject to her continued service.
CG Oncology, Inc. director Leonard E. Post reported an exercise-and-sale transaction plus a new option grant. He exercised 1,000 stock options at $0.60 per share and sold 1,000 common shares at $54.50 per share under a pre-arranged Rule 10b5-1 trading plan. He also received a fully vested grant of 9,354 director stock options with a $56.09 exercise price, while another option grant for 9,354 shares vests monthly after June 4, 2026. Following these transactions, he holds 1,000 common shares and 116,077 director stock options.
CG Oncology director Susan E. Graf received a grant of stock options covering 9,354 shares of common stock. The options have an exercise price of $56.09 per share and expire on June 3, 2036. They vest in 12 equal monthly installments beginning after June 4, 2026, subject to her continuous service, with any remaining unvested portion vesting at the next annual stockholder meeting if that occurs within a year. Following this grant, she holds 9,354 director stock options directly.
CG Oncology director James Mulay reported an exercise-and-sale transaction in the company’s common stock. On April 17, 2026, he exercised options to acquire 15,600 shares of common stock at $36.63 per share, then sold the same 15,600 shares in an open-market transaction at a weighted average price of $73.01 per share.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 6, 2025, indicating they were scheduled in advance rather than timed discretionarily. After these transactions, Mulay reported holding no shares of common stock or related director stock options directly.
CG Oncology, Inc. reported that President and COO Bellete Ambaw received a grant of employee stock options. The award covers 107,508 options to buy common stock at an exercise price of $67.68 per share, expiring on April 14, 2036.
According to the footnote, 1/48th of the options vest monthly after the April 15, 2026 vesting commencement date, contingent on Ambaw’s continuous service. Following this grant, Ambaw directly holds 107,508 derivative securities linked to CG Oncology common stock.
CG Oncology, Inc. reported that Chief Medical Officer Kasturi Vijay received an employee stock option grant for 79,216 shares of common stock. The option has an exercise price of $67.68 per share, expires on April 14, 2036, and represents a compensation-related award rather than an open-market trade.
These options vest over time: 1/48 of the shares vest monthly after April 15, 2026, as long as Vijay continues providing service to the company. Following this grant, Vijay holds derivative rights to acquire 79,216 shares through this option.
CG Oncology, Inc. reported that officer Joshua F. Patterson received an employee stock option grant covering 45,266 shares of common stock. The option has an exercise price of $67.68 per share and expires on April 14, 2036.
According to the terms, 1/48th of the option vests each month after the vesting commencement date of April 15, 2026, as long as Patterson remains in continuous service with the company. This is a compensation-related equity award rather than an open-market stock purchase or sale.
CG Oncology, Inc. reported that Chief Financial Officer James M. Detore received an employee stock option grant covering 90,574 shares of common stock. The option has an exercise price of $67.68 per share and expires on April 14, 2036.
According to the vesting terms, the option vests over four years starting on April 15, 2026, with 25% of the shares vesting 12 months after that date and the remaining 75% vesting in 36 equal monthly installments over the following three years. This is a compensation-related award rather than an open-market purchase.
CG Oncology, Inc. reported that Chief Executive Officer Arthur Kuan received a grant of employee stock options covering 271,600 shares of common stock. The options have an exercise price of $67.68 per share and expire on April 14, 2036.
According to the award terms, 1/48th of the shares subject to the option vest monthly following April 15, 2026, as long as Kuan continues to provide services to the company through each vesting date. After this grant, he holds 271,600 derivative securities linked to common stock.
CG Oncology director James Mulay exercised stock options for 1,964 shares of Common Stock and sold the same number of shares in pre-planned trades. He exercised Director Stock Options for 654 shares at $3.72 and 1,310 shares at $12.59 per share, then sold 654 and 1,310 shares at $63.50 per share in open-market transactions. The sales were made under a Rule 10b5-1 trading plan adopted on June 6, 2025, indicating these trades were scheduled in advance rather than timed discretionarily.
CG Oncology, Inc. Chief Executive Officer Arthur Kuan exercised employee stock options to acquire common stock. He exercised options covering 64,612 shares at an exercise price of $1.72 per share through a net exercise. According to the footnote, he received 62,765 shares of common stock, while 1,847 shares were withheld to cover obligations related to the exercise, and he paid the remaining amount in cash. This withholding is recorded as a tax-related disposition and is explicitly described as not representing a sale. Following these transactions, Kuan directly holds 198,916 shares of CG Oncology common stock.
CG Oncology, Inc. Chief Executive Officer Arthur Kuan exercised employee stock options and increased his direct ownership. On March 4, 2026, he exercised options for 102,871 shares of common stock at $1.72 per share, receiving 100,000 shares after a net exercise in which the company withheld 2,871 shares and he paid the remaining exercise price in cash. A related disposition of 2,871 shares at $61.61 per share was recorded for payment of the exercise price or tax liability and, as noted, does not represent an open-market sale. Following these transactions, Kuan directly owned 136,151 shares of CG Oncology common stock.
CG Oncology director James Mulay reported option exercises and share sales for CG Oncology, Inc. common stock on January 9, 2026. He exercised a director stock option for 654 shares at an exercise price of $3.72 per share and sold 654 shares of common stock at $44.16 per share. He also exercised a second director stock option for 10,491 shares at an exercise price of $12.59 per share and sold 10,491 shares at $52.99 per share. The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on June 6, 2025, and that the options vest in 36 monthly installments beginning in July 2023 and January 2024, respectively.
CG Oncology, Inc. (CGON) disclosed a new stock option grant to a director. On 11/24/2025, the reporting person received a director stock option to purchase 20,889 shares of CG Oncology common stock at an exercise price of $43.56 per share. The option expires on 11/23/2035 if not exercised.
According to the vesting terms, 1/36th of the shares subject to the option vest monthly following November 24, 2025, as long as the director continues to provide service to the company through each vesting date. After this grant, the reporting person beneficially owns 20,889 derivative securities directly in the form of these stock options.
CG Oncology, Inc. (CGON) director Leonard Post reported a small insider transaction involving company stock. On 11/17/2025, he exercised a director stock option to acquire 1,000 shares of common stock at an exercise price of $0.6 per share, then sold those 1,000 shares of common stock at a price of $41.43 per share. After these transactions, he reported owning 0 shares of common stock directly.
Following the option exercise, he continued to hold 117,077 derivative securities in the form of stock options, which are exercisable until 07/08/2028 and are fully vested. The filing notes that the sale was carried out under a Rule 10b5-1 trading plan that Leonard Post adopted on September 6, 2024, indicating the trades were pre-arranged under that plan.
CG Oncology (CGON): Form 4 insider activity — A director reported transactions on 10/13/2025. The reporting person exercised 1,000 stock options at $0.60 (Code M) and sold 1,000 shares at $43.25 (Code S).
The sale was effected under a Rule 10b5-1 trading plan adopted on September 6, 2024. Following these transactions, the reporting person held 0 shares of common stock directly and 118,077 derivative securities (director stock options) directly.
Director James J. Mulay completed option-related transactions on 10/09/2025. He exercised 5,903 stock options at an exercise price of $3.72 per share, then sold the resulting 5,903 shares at $43.99 per share pursuant to a Rule 10b5-1 trading plan adopted on 06/06/2025. After these transactions the reporting person beneficially owns 0 shares of common stock and retains derivative exposure showing 1,962 derivative securities reported as beneficially owned following the transactions. The reported stock option vests in 36 monthly installments beginning on 07/14/2023 and has an expiration date of 06/13/2033. The Form 4 was signed on 10/10/2025 by an attorney-in-fact.
Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions dated 09/30/2025. The filing shows a purchase/acquisition of 5,000 common shares and a simultaneous sale/disposition of 5,000 common shares sold under a Rule 10b5-1 trading plan at a weighted average price of $40.09. The reporter holds a fully vested director stock option with an exercise price of $0.60 covering 5,000 shares and reports total beneficial ownership of 119,077 shares following the transactions. The sale was effected under a 10b5-1 plan adopted on 09/06/2024.
Insider transactions by CG Oncology (CGON) director James J. Mulay on 09/29/2025: Mr. Mulay exercised 12,755 fully vested director stock options at an exercise price of $1.82 per share, converting them into 12,755 shares of common stock. On the same date those 12,755 shares were sold under a Rule 10b5-1 trading plan at a weighted average price of $39.19 per share (individual sale prices ranged from $38.99 to $39.41). Following the reported transactions, the reporting person holds no common shares but retains the director stock option record showing 12,755 underlying shares with an exercise price of $1.82 and an expiration of 07/18/2031. The Form 4 was signed by an attorney-in-fact.
James J. Mulay, a director of CG Oncology, Inc. (CGON), reported option exercises and immediate sales on September 18-19, 2025. On 09/18/2025 he exercised Director Stock Options to acquire 19,112 shares at an exercise price of $1.82 per share and, pursuant to a Rule 10b5-1 trading plan adopted June 6, 2025, sold those 19,112 shares at a weighted average price of $39.01. On 09/19/2025 he exercised an additional 3,574 options at $1.82 and sold those 3,574 shares at $38.99. The filing states the options were fully vested and the sales reduced the reported non-derivative beneficial ownership to zero following the transactions. The form is signed by an attorney-in-fact on behalf of Mr. Mulay.
Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions dated 09/15/2025. He exercised a director stock option with a $0.60 exercise price to acquire 1,000 shares (option fully vested). On the same date he sold 1,000 shares at $35.10 per share; the filing states the sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person on 09/06/2024. Following these transactions, the filing reports total beneficial ownership of 124,077 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Post on 09/16/2025.